B6.Cg-Hnrnpdtm1.2Dkon/Flmg

Status

Available to order

EMMA IDEM:08427
Citation informationRRID:IMSR_EM:08427 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

International strain nameB6.Cg-Hnrnpdtm1.2Dkon/Flmg
Alternative nameB6.Cg-Hnrnpdtm1.2Dkon/Flmg
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolHnrnpdtm1.2Dkon
Gene/Transgene symbolHnrnpd

Information from provider

ProviderDimitris KONTOYIANNIS
Provider affiliationImmunology, BSRC Al. Fleming
Genetic informationThe construct was created with a BAC vector modified by VelociGene technology (Regeneron). It consisted of a neo cassette flanked by two FLPe recombination sites and two loxP sites. In the floxed allele FLPe recombination resulted in excision of the neo cassette; cre-mediated recombination removed the floxed exons 3 and 4, resulting in the expression of a mutated form of the HNRNPD (AUF1) protein that lacks the two RNA recognition motifs (RRMs), prohibiting RNA recognition.
Phenotypic informationHomozygous:
Homozygous mutant mice for the Hnrnpdtm1.2Dkon allele display a sex-independent 50% divergence in Mendelian birth ratio and die before the end of gestation. Homozygous mice that are born are growth-retarded and sterile. Evaluation showed that homozygous mutant mice are almost half-sized in comparison to the wild-type mice.

Heterozygous:
No overt phenotype
References
  • Inactivation of AUF1 in Myeloid Cells Protects From Allergic Airway and Tumor Infiltration and Impairs the Adenosine-Induced Polarization of Pro-Angiogenic Macrophages.;Gargani Sofia, Lourou Niki, Arapatzi Christina, Tzanos Dimitris, Saridaki Marania, Dushku Esmeralda, Chatzimike Margarita, Sidiropoulos Nikolaos D, Andreadou Margarita, Ntafis Vasileios, Hatzis Pantelis, Kostourou Vassiliki, Kontoyiannis Dimitris L, ;2022;Frontiers in immunology;13;752215; 35222366
Homozygous fertileno
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreB.S.R.C. Alexander Fleming, Vari, Greece
Animals used for archivingheterozygous C57BL/6J males

Disease and phenotype information

IMPC phenotypes (gene matching)
  • increased basophil cell number / IMPC
  • decreased leukocyte cell number / IMPC
  • increased thigmotaxis / IMPC
  • increased eosinophil cell number / IMPC
  • increased anxiety-related response / IMPC
  • abnormal behavior / IMPC
  • decreased lymphocyte cell number / IMPC
  • decreased locomotor activity / IMPC
MGI phenotypes (gene matching)
  • kidney hemorrhage / MGI
  • decreased body weight / MGI
  • decreased body size / MGI
  • increased susceptibility to bacterial infection / MGI
  • abnormal macrophage physiology / MGI
  • fetal growth retardation / MGI
  • increased circulating aspartate transaminase level / MGI
  • increased blood urea nitrogen level / MGI
  • increased circulating tumor necrosis factor level / MGI
  • increased susceptibility to endotoxin shock / MGI
  • decreased birth weight / MGI
  • decreased birth body size / MGI

Literature references

  • Inactivation of AUF1 in Myeloid Cells Protects From Allergic Airway and Tumor Infiltration and Impairs the Adenosine-Induced Polarization of Pro-Angiogenic Macrophages.;Gargani Sofia, Lourou Niki, Arapatzi Christina, Tzanos Dimitris, Saridaki Marania, Dushku Esmeralda, Chatzimike Margarita, Sidiropoulos Nikolaos D, Andreadou Margarita, Ntafis Vasileios, Hatzis Pantelis, Kostourou Vassiliki, Kontoyiannis Dimitris L, ;2022;Frontiers in immunology;13;752215; 35222366

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).